Jazz Pharma Q2 revenue $932.9M (+24% YoY), affirms FY2022 guidance, net leverage target met early

Jazz Pharmaceuticals plc

2022-Q2 EPS reported $0.57 revenue$1,746,599,000

Q2 2022 total revenues $932.9M, up 24% YoY; strong commercial execution across franchises.
2022 total revenue guidance affirmed at $3.5-3.7B; GAAP guidance updated for FX movements.
Net leverage ratio 3.2x, achieving target six months ahead of schedule, providing balance sheet flexibility.
Milestones: more patients on Xywav than Xyrem; JZP458 MAA submitted to EMA; JZP815 IND cleared by FDA.
Divested Sunosi to sharpen focus on strategic priorities; pipeline expanded with JZP441 and JZP898.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.